Dimedazol

Dimedazol

SCHEMBL61387

Cc1cc2nc[nH]c2cc1C.Fc1c(F)c(F)c([Al](c2c(F)c(F)c(F)c(F)c2F)c2c(F)c(F)c(F)c(F)c2F)c(F)c1F.Fc1c(F)c(F)c([Al](c2c(F)c(F)c(F)c(F)c2F)c2c(F)c(F)c(F)c(F)c2F)c(F)c1F

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
APEX1 P27695 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MMP12 P39900 1/20 0.37
QPCT Q16769 3/20 0.36
PRKCI P41743 1/20 0.36
RAD52 P43351 1/20 0.35
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34
POLB P06746 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimedazol SCHEMBL28639998 1.00 MAPT (0.45) MAPTKDM4EALDH1A1APEX1RECQL
Dimedazol SCHEMBL726090 0.94 MAPT (0.41) MAPTKDM4EALDH1A1APEX1RECQL
Dimedazol SCHEMBL312977 0.84 MAPT (0.56) MAPTKDM4EALDH1A1APEX1RECQL
Dimedazol SCHEMBL28621495 0.82 MAPT (0.44) MAPTKDM4EALDH1A1APEX1RECQL
Dimedazol SCHEMBL28640693 0.82 MAPT (0.44) MAPTKDM4EALDH1A1APEX1RECQL
Dimedazol SCHEMBL61658 0.82 MAPT (0.44) MAPTKDM4EALDH1A1APEX1RECQL
Dimedazol SCHEMBL727732 0.77 MAPT (0.40) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL12113061 0.77 MAPT (0.61) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL12121772 0.77 MAPT (0.56) MAPTKDM4EALDH1A1APEX1RECQL
Dimedazol SCHEMBL29097803 0.75 MAPT (0.47) MAPTKDM4EALDH1A1APEX1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4722287-B2 2011-07-13 JP claimed
EP-1228109-B1 SUPPORTED CATALYST COMPRISING EXPANDED ANIONS DOW GLOBAL TECHNOLOGIES INC (US) 2006-02-01 EP claimed
US-6716786-B1 LEWIS ACIDS AND BASES THE DOW CHEMICAL COMPANY 2004-04-06 US claimed
EP-1056752-B1 Catalyst activators comprising expanded anions DOW GLOBAL TECHNOLOGIES INC (US) 2003-06-25 EP claimed
EP-1228109-A1 SUPPORTED CATALYST COMPRISING EXPANDED ANIONS THE DOW CHEMICAL COMPANY (US) 2002-08-07 EP claimed
US-6395671-B2 ANION CONTAINING TWO LEWIS BASIC SITES WHICH ARE COORDINATED TO LEWIS ACIDS; FOR OLEFIN POLYMERIZATION THE DOW CHEMICAL COMPANY 2002-05-28 US claimed
US-6376406-B1 COORDINATION POLYMERIZATION CATALYSTS FOR ALPHA-OLEFINS THE DOW CHEMICAL COMPANY 2002-04-23 US claimed
US-20010027161-A1 Catalyst activators comprising expanded anions THE DOW CHEMICAL COMPANY 2001-10-04 US claimed
WO-2001023442-A1 SUPPORTED CATALYST COMPRISING EXPANDED ANIONS THE DOW CHEMICAL COMPANY (US) 2001-04-05 WO claimed
EP-1056752-A1 CATALYST ACTIVATORS COMPRISING EXPANDED ANIONS THE DOW CHEMICAL COMPANY (US) 2000-12-06 EP claimed
WO-1999042467-A1 CATALYST ACTIVATORS COMPRISING EXPANDED ANIONS THE DOW CHEMICAL COMPANY (US) 1999-08-26 WO claimed
EP-3519455-B1 MULTI- OR DUAL-HEADED COMPOSITIONS USEFUL FOR CHAIN SHUTTLING AND PROCESS TO PREPARE THE SAME DOW GLOBAL TECHNOLOGIES LLC (US) 2024-04-10 EP disclosed
EP-4234594-A1 CURABLE COMPOSITIONS COMPRISING UNSATURATED POLYOLEFINS Dow Global Technologies LLC (US) 2023-08-30 EP disclosed
EP-2024402-B2 HIGH TEMPERATURE SOLUTION POLYMERIZATION PROCESS DOW GLOBAL TECHNOLOGIES LLC (US) 2023-01-25 EP disclosed
US-20220204716-A1 CURABLE COMPOSITIONS COMPRISING UNSATURATED POLYOLEFINS DOW GLOBAL TECHNOLOGIES LLC 2022-06-30 US disclosed
WO-2001023442-A1 SUPPORTED CATALYST COMPRISING EXPANDED ANIONS THE DOW CHEMICAL COMPANY (US) 2001-04-05 WO disclosed
EP-1056752-A1 CATALYST ACTIVATORS COMPRISING EXPANDED ANIONS THE DOW CHEMICAL COMPANY (US) 2000-12-06 EP disclosed
WO-2000020462-A2 BRIDGED METAL COMPLEXES FOR GAS PHASE POLYMERIZATIONS BP CHEMICALS LIMITED (GB) 2000-04-13 WO disclosed
WO-2000020426-A1 BRIDGED METAL COMPLEXES THE DOW CHEMICAL COMPANY (US) 2000-04-13 WO disclosed
WO-1999042467-A1 CATALYST ACTIVATORS COMPRISING EXPANDED ANIONS THE DOW CHEMICAL COMPANY (US) 1999-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204716-A1 CURABLE COMPOSITIONS COMPRISING UNSATURATED POLYOLEFINS ACSL6, ELOVL6, ALOX5 MAPT 369/4885KDM4E 2783/4885ALDH1A1 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.